Biology
How growth-hormone axis peptides differ
GHRH analogs versus ghrelin mimetics, and why tesamorelin is not CJC-1295.
Peptide Help editorial team · Published Aug 12, 2026 · Updated Aug 20, 2026 · 1 min read
The pituitary can release growth hormone after a GHRH-receptor signal or after a ghrelin-receptor (GH secretagogue) signal. Those are different keys.
Tesamorelin is an approved GHRH analog for a specific HIV-associated lipodystrophy indication. CJC-1295 is a long-acting GHRH analog with limited human pharmacology. Ipamorelin and GHRP-2/6 act at the ghrelin receptor. Lumping them as 'GH peptides' hides those differences.
IGF-I is not a lifestyle score
Raising GH and IGF-I is a biological effect, not automatically a benefit. Metabolic, proliferative, and fluid-retention issues are among reasons GH-axis drugs are regulated when they are medicines at all.
Cite this page
Use this citation if a paper, review, or lab note needs to point at this write-up. Peptide Help does not sell links and does not pay for citations.
Peptide Help editorial team. (2026). How growth-hormone axis peptides differ. Peptide Help. https://knowspeptides.com/articles/how-gh-axis-peptides-differ
Sources
Growth Hormone Research
Tesamorelin
Growth hormone–releasing factor analog approved to reduce excess abdominal fat in HIV-infected adults with lipodystrophy — not a general weight-loss medicine.
View peptide →
Growth Hormone Research
CJC-1295
Long-acting GHRH analog studied in healthy adults for prolonged GH and IGF-I secretion. Not an approved therapy for general use.
View peptide →
Growth Hormone Research
Ipamorelin
Selective ghrelin-receptor GH secretagogue characterized mainly in experimental models. Not an approved medicine.
View peptide →
Growth Hormone Research
Sermorelin
GHRH (1-29) analog that was previously marketed in the U.S. Current routine availability and approved status should not be assumed from historical branding.
View peptide →